These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 22009113)

  • 1. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice.
    Bal SM; Slütter B; Verheul R; Bouwstra JA; Jiskoot W
    Eur J Pharm Sci; 2012 Mar; 45(4):475-81. PubMed ID: 22009113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?
    Slütter B; Bal SM; Que I; Kaijzel E; Löwik C; Bouwstra J; Jiskoot W
    Mol Pharm; 2010 Dec; 7(6):2207-15. PubMed ID: 21043518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
    Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W
    Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.
    Slütter B; Jiskoot W
    J Control Release; 2010 Nov; 148(1):117-121. PubMed ID: 20600405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination.
    Bal SM; Hortensius S; Ding Z; Jiskoot W; Bouwstra JA
    Vaccine; 2011 Jan; 29(5):1045-52. PubMed ID: 21129393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations.
    Bal SM; Slütter B; van Riet E; Kruithof AC; Ding Z; Kersten GF; Jiskoot W; Bouwstra JA
    J Control Release; 2010 Mar; 142(3):374-83. PubMed ID: 19932723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
    Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination.
    Verheul RJ; Slütter B; Bal SM; Bouwstra JA; Jiskoot W; Hennink WE
    J Control Release; 2011 Nov; 156(1):46-52. PubMed ID: 21784113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen.
    Slütter B; Soema PC; Ding Z; Verheul R; Hennink W; Jiskoot W
    J Control Release; 2010 Apr; 143(2):207-14. PubMed ID: 20074597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunisation.
    Bal SM; Slütter B; Jiskoot W; Bouwstra JA
    Vaccine; 2011 May; 29(23):4025-32. PubMed ID: 21443959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration.
    Boonyo W; Junginger HE; Waranuch N; Polnok A; Pitaksuteepong T
    J Control Release; 2007 Aug; 121(3):168-75. PubMed ID: 17644205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and evaluation of antigen/N-trimethylaminoethylmethacrylate chitosan conjugates for nasal immunization.
    Liu Q; Zhang C; Zheng X; Shao X; Zhang X; Zhang Q; Jiang X
    Vaccine; 2014 May; 32(22):2582-90. PubMed ID: 24681230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
    Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
    J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
    Hagenaars N; Verheul RJ; Mooren I; de Jong PH; Mastrobattista E; Glansbeek HL; Heldens JG; van den Bosch H; Hennink WE; Jiskoot W
    J Control Release; 2009 Dec; 140(2):126-33. PubMed ID: 19712713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
    Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice.
    Huang CF; Wang CC; Wu TC; Chu CH; Peng HJ
    Ann Allergy Asthma Immunol; 2007 Nov; 99(5):443-52. PubMed ID: 18051215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally.
    Mangal S; Pawar D; Garg NK; Jain AK; Vyas SP; Rao DS; Jaganathan KS
    Vaccine; 2011 Jul; 29(31):4953-62. PubMed ID: 21575664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: Impact of formulation on physicochemical and immunological characteristics.
    Tafaghodi M; Saluja V; Kersten GF; Kraan H; Slütter B; Amorij JP; Jiskoot W
    Vaccine; 2012 Aug; 30(36):5341-8. PubMed ID: 22749834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
    San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
    Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model.
    Dabaghian M; Latifi AM; Tebianian M; NajmiNejad H; Ebrahimi SM
    Vaccine; 2018 May; 36(20):2886-2895. PubMed ID: 29627234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.